Delhi High Court (Division Bench), 2015 (RFA (OS) Nos. 92/2012 & 103/2012)
1. Background and Context
The dispute concerned Patent No. IN 196774, granted to F. Hoffmann-La Roche for the compound Erlotinib Hydrochloride, a pharmaceutical substance used in the treatment of non-small cell lung cancer and marketed by Roche as Tarceva. Cipla launched a generic version marketed as Erlocip, leading Roche to institute infringement proceedings.
This litigation followed earlier interim injunction proceedings in 2008–2009, where injunctions were refused on grounds of public interest, affordability, and prima facie doubts over patent validity. After a full trial, the Single Judge upheld the validity of the patent but dismissed the infringement claim. Both parties appealed, leading to the present Division Bench judgment.
The case raised complex and foundational questions relating to patent validity, inventive step, Section 3(d), claim construction, and pharmaceutical infringement under Indian patent law.
2. Issues for Determination
The Division Bench addressed, inter alia, the following issues:
- Whether Patent IN 196774 was liable to be revoked for lack of inventive step, anticipation, or non-compliance with statutory disclosure obligations.
- The correct interpretation and application of Section 3(d) of the Patents Act, 1970.
- Whether Cipla’s product Erlocip infringed Roche’s patent claims.
- The appropriate standard for claim construction in pharmaceutical patents.
- The relationship between a patented “substance”, its polymorphic forms, and infringement analysis.
3. Key Holdings of the Court
- The Court upheld the validity of Patent IN 196774, rejecting Cipla’s challenges based on lack of inventive step and Section 3(d).
- It held that Section 3(d) is not a defence to infringement, and rejection of a separate polymorph patent does not automatically place that polymorph outside the scope of an existing valid patent.
- The Court clarified that Erlotinib Hydrochloride as a molecule was the subject of the patent, and polymorphism relates to physical form, not chemical identity.
- On infringement, the Court held that Roche failed to discharge the burden of proof, particularly due to insufficient evidence establishing that Cipla’s product fell within the scope of Claim 1 as properly construed.
- The appeal by Roche was dismissed, and Cipla’s appeal challenging validity was also rejected.
4. Statutory Provisions Applied
Section 2(1)(j) & 2(1)(ja), Patents Act, 1970
(Definition of “invention” and “inventive step”)
Judicial Interpretation:
The Court reaffirmed that inventive step requires both technical advancement and non-obviousness, and that pharmaceutical inventions are not subject to a separate or diluted standard.
Section 3(d), Patents Act, 1970
“The mere discovery of a new form of a known substance which does not result in the enhancement of the known efficacy of that substance…”
Judicial Interpretation:
The Court treated Section 3(d) as a threshold patentability provision, not as an infringement shield. It clarified that:
- rejection of a polymorph application under Section 3(d) does not imply freedom to infringe an existing product patent;
- Section 3(d) recognises incremental innovation but filters out non-efficacious variants.
Section 48, Patents Act, 1970
(Rights of Patentee)
Judicial Interpretation:
Patent rights extend to the patented product itself, irrespective of the form in which it is made, unless claims are expressly limited.
Section 64, Patents Act, 1970
(Grounds for Revocation)
Judicial Interpretation:
The Court reiterated that revocation requires strict proof, and the burden lies on the challenger to establish invalidity on a balance of probabilities.
5. Claim Construction and Infringement Analysis
A significant contribution of this judgment lies in its detailed treatment of claim construction. The Court emphasised:
- Claims define the scope of monopoly and must be construed objectively, through the eyes of a person skilled in the art.
- Where claims are clear, they cannot be expanded or restricted by reference to subsequent conduct or abandoned applications.
- Polymorphism is an inter-molecular phenomenon, whereas the patented invention related to an intra-molecular chemical structure.
However, on facts, Roche failed to establish—through credible experimental or analytical evidence—that Cipla’s product corresponded to the patented claim. As a result, infringement was not proved.
6. Doctrinal Significance
This judgment occupies a critical position in Indian pharmaceutical patent jurisprudence because it:
- Clarifies the product–substance–polymorph distinction under Indian law;
- Establishes that Section 3(d) does not dilute infringement analysis;
- Reinforces rigorous evidentiary standards in patent infringement suits;
- Aligns Indian claim construction principles with comparative common-law doctrine while retaining statutory fidelity.
The Court also harmonised this decision with the Supreme Court’s ruling in Novartis AG v. Union of India, particularly on the interpretation of Section 3(d).
7. Why This Case Is a Landmark
Cipla v. Roche (2015) is a landmark because it:
- Consolidated post-Novartis pharmaceutical patent doctrine in India;
- Prevented misuse of Section 3(d) as a blanket defence to infringement;
- Provided one of the most comprehensive Indian judicial discussions on claim construction;
- Balanced patent enforcement with evidentiary discipline and public interest considerations.
It remains a leading authority on pharmaceutical patent infringement and validity under the Patents Act, 1970.